
Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations – Canada NewsWire
Searching for your content…Phone 877-269-7890 from 8 AM – 10 PM ET Contact Cision 877-269-7890 from 8 AM – 10 PM ET News provided byJun 08, 2022,


